WuXi Biologics (Cayman) 관리

관리 기준 확인 2/4

WuXi Biologics (Cayman) CEO는 Chris Chen, Jan2016 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 CN¥ 96.91M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 $ 26.80M 가치에 해당하는 회사 주식의 0.35% 직접 소유합니다. 26.80M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 7.2 년입니다.

주요 정보

Chris Chen

최고 경영자

CN¥96.9m

총 보상

CEO 급여 비율	4.1%
CEO 임기	8.8yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Chen 의 보수는 WuXi Biologics (Cayman) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

보상 대 시장: Chris 의 총 보상 ($USD 13.38M )은 US 시장( $USD 7.78M ).

보상과 수익: Chris 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Chris Chen (51 yo)

8.8yrs

테뉴어

CN¥96,911,000

보상

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

리더십 팀

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.8yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% $ 1.0m
Ming Tu	CFO & Executive VP	3yrs	데이터 없음	데이터 없음
Lihua Yu	COO & Senior VP	less than a year	데이터 없음	데이터 없음
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	데이터 없음	데이터 없음
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	데이터 없음	데이터 없음
Lina Fan	Senior VP & Head of Investor Relations	less than a year	데이터 없음	데이터 없음
He Wang	Chief Compliance Officer	2.2yrs	데이터 없음	데이터 없음
Li Xiong	VP & Head of Global Human Resources	no data	데이터 없음	데이터 없음
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	데이터 없음	데이터 없음
Keqiang Shen	Chief Digital Officer	4.8yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: WXIB.F 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.8yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% $ 1.0m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% $ 47.8k
James Larrick	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
David D. Ho	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% $ 40.2k
Yanling Cao	Non-Executive Director	8.5yrs	데이터 없음	데이터 없음
Yibing Wu	Non-Executive Director	8.5yrs	데이터 없음	데이터 없음
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% $ 375.9k

7.2yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: WXIB.F 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

WuXi Biologics (Cayman) 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for € 110 million.

Arcus Biosciences, Inc. Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

WuXi Biologics and AB2 Bio Ltd. Announces Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

WuXi Biologics (Cayman) Inc. has completed a Follow-on Equity Offering in the amount of HKD 6.165 billion.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령